FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968407633> ?p ?o ?g. }

• W2968407633 abstract "As new biosimilar and follow-on insulins enter the market, more data are needed on safety, effectiveness, and patterns of use for these products to inform prescriber and patient decision-making regarding treatment. Additionally, data are needed regarding real-world patterns of use to inform future studies comparing the safety and effectiveness of bio-similars to already approved agents for diabetes treatment.To analyze the medication use patterns, adverse events, and availability of glycated hemoglobin (A1c) values for adult patients with type 2 diabetes mellitus (T2DM) who use long-acting insulin (LAI) or neutral protamine Hagedorn (NPH), an intermediate-acting insulin.We used the Biologics and Biosimilars Collective Intelligence Consortium's (BBCIC) distributed research network (DRN) for this descriptive analysis. The analysis time frame was January 1, 2011, to September 30, 2015, and included patients continuously insured for at least 183 days before the first date of a filled prescription for LAI or NPH insulin alone or with rapid- or short-acting insulin or sulfonylureas, whether newly starting insulin or switching to a different product. Insulin exposure episodes were the unit of analysis, and patients were classified in cohorts according to treatment. We followed patients until end of health plan enrollment or the end of the study period. We used occurrence of a study outcome, switch to another medication regimen, discontinuation of the current medication, or study end date to mark the end of an insulin episode. We describe demographics and availability of A1c values for analysis. Study outcomes included severe hypoglycemic events and major adverse cardiac events (MACE).We identified 103,951 patients with T2DM from a database of 39.1 million patients with commercial or Medicare Advantage pharmacy and medical benefits, who contributed 279,533 unique insulin exposure episodes. Most episodes (89%) included patients using LAI, and 52% of patients contributed data to 2 or more exposure cohorts. Insulin episodes lasted an average of 3.5 months, and patients had an average follow-up of 8.6 months. The unadjusted rate of severe hypoglycemic events requiring medical attention was 96.9 per 10,000 patient-years at risk (10kPYR). The unadjusted incident MACE rate was 676.9 events per 10kPYR. 38,330 T2DM patients in the BBCIC DRN had a baseline A1c available, and of those, less than 50% had a follow-up A1c result.Among patients with T2DM, our observed insulin patterns of use and rates of severe hypoglycemic outcomes and MACE are consistent with other studies. We noted a paucity of A1c results available, which implies that additional data sources may be needed to augment the BBCIC DRN.This study was coordinated and funded by the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) and represents the independent findings of the BBCIC Insulins Principal Investigator and the BBCIC Insulins Research Team. Lockhart is employed by the BBCIC and the Academy of Managed Care Pharmacy (AMCP). Eichelberger was employed by the BBCIC and AMCP at the time of this study. McMahill-Walraven is employed by Aetna, a CVS Health business. Panozzo, Marshall, and Brown are employed by Harvard Pilgrim Healthcare Institute. Aetna was reimbursed for data and analytic support from Harvard Pilgrim Healthcare Institute and the Reagan Udall Foundation for the U.S. Food and Drug Administration. Aetna receives external funding through research grants and subcontracts with Harvard Pilgrim Healthcare Institute, which are funded by the FDA, NIH, PCORI, BBCIC, Pfizer, and GSK; the Reagan-Udall Foundation for IMEDS; and PCORI for the ADAPTABLE Study. This work was previously presented as a poster at AMCP Nexus 2018; October 22-25, 2018; in Orlando, FL." @default.
• W2968407633 created "2019-08-22" @default.
• W2968407633 creator A5001604242 @default.
• W2968407633 creator A5007502154 @default.
• W2968407633 creator A5015827067 @default.
• W2968407633 creator A5022942507 @default.
• W2968407633 creator A5035435309 @default.
• W2968407633 creator A5039530685 @default.
• W2968407633 creator A5057514738 @default.
• W2968407633 creator A5062043780 @default.
• W2968407633 creator A5067489486 @default.
• W2968407633 date "2019-11-01" @default.
• W2968407633 modified "2023-09-27" @default.
• W2968407633 title "Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus" @default.
• W2968407633 cites W1484976590 @default.
• W2968407633 cites W172609984 @default.
• W2968407633 cites W1864510953 @default.
• W2968407633 cites W1902158305 @default.
• W2968407633 cites W1947934229 @default.
• W2968407633 cites W1975663485 @default.
• W2968407633 cites W1997175144 @default.
• W2968407633 cites W2045030413 @default.
• W2968407633 cites W2048981123 @default.
• W2968407633 cites W2069381373 @default.
• W2968407633 cites W2081015392 @default.
• W2968407633 cites W2087018232 @default.
• W2968407633 cites W2098705100 @default.
• W2968407633 cites W2102108180 @default.
• W2968407633 cites W2103828712 @default.
• W2968407633 cites W2142830692 @default.
• W2968407633 cites W2147764623 @default.
• W2968407633 cites W2157836715 @default.
• W2968407633 cites W2158666727 @default.
• W2968407633 cites W2164733897 @default.
• W2968407633 cites W2171294019 @default.
• W2968407633 cites W2209559096 @default.
• W2968407633 cites W2209601681 @default.
• W2968407633 cites W2241751268 @default.
• W2968407633 cites W2289939153 @default.
• W2968407633 cites W2302447233 @default.
• W2968407633 cites W2403703304 @default.
• W2968407633 cites W2425644022 @default.
• W2968407633 cites W2488823151 @default.
• W2968407633 cites W2572398654 @default.
• W2968407633 cites W2745310286 @default.
• W2968407633 cites W2765979443 @default.
• W2968407633 cites W2770400568 @default.
• W2968407633 cites W2791704486 @default.
• W2968407633 cites W2792628484 @default.
• W2968407633 cites W2798206180 @default.
• W2968407633 cites W2808944450 @default.
• W2968407633 cites W2888195583 @default.
• W2968407633 cites W2897218960 @default.
• W2968407633 cites W2901626405 @default.
• W2968407633 cites W2902452806 @default.
• W2968407633 cites W2907088970 @default.
• W2968407633 cites W2909029941 @default.
• W2968407633 cites W2913956994 @default.
• W2968407633 doi "https://doi.org/10.18553/jmcp.2019.19042" @default.
• W2968407633 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31405345" @default.
• W2968407633 hasPublicationYear "2019" @default.
• W2968407633 type Work @default.
• W2968407633 sameAs 2968407633 @default.
• W2968407633 citedByCount "2" @default.
• W2968407633 countsByYear W29684076332022 @default.
• W2968407633 crossrefType "journal-article" @default.
• W2968407633 hasAuthorship W2968407633A5001604242 @default.
• W2968407633 hasAuthorship W2968407633A5007502154 @default.
• W2968407633 hasAuthorship W2968407633A5015827067 @default.
• W2968407633 hasAuthorship W2968407633A5022942507 @default.
• W2968407633 hasAuthorship W2968407633A5035435309 @default.
• W2968407633 hasAuthorship W2968407633A5039530685 @default.
• W2968407633 hasAuthorship W2968407633A5057514738 @default.
• W2968407633 hasAuthorship W2968407633A5062043780 @default.
• W2968407633 hasAuthorship W2968407633A5067489486 @default.
• W2968407633 hasBestOaLocation W29684076331 @default.
• W2968407633 hasConcept C126322002 @default.
• W2968407633 hasConcept C134018914 @default.
• W2968407633 hasConcept C177713679 @default.
• W2968407633 hasConcept C187212893 @default.
• W2968407633 hasConcept C197934379 @default.
• W2968407633 hasConcept C2776664568 @default.
• W2968407633 hasConcept C2777180221 @default.
• W2968407633 hasConcept C2778715236 @default.
• W2968407633 hasConcept C2778804033 @default.
• W2968407633 hasConcept C2779306644 @default.
• W2968407633 hasConcept C2779920387 @default.
• W2968407633 hasConcept C2780668416 @default.
• W2968407633 hasConcept C2910068830 @default.
• W2968407633 hasConcept C3019948211 @default.
• W2968407633 hasConcept C555293320 @default.
• W2968407633 hasConcept C71924100 @default.
• W2968407633 hasConceptScore W2968407633C126322002 @default.
• W2968407633 hasConceptScore W2968407633C134018914 @default.
• W2968407633 hasConceptScore W2968407633C177713679 @default.
• W2968407633 hasConceptScore W2968407633C187212893 @default.
• W2968407633 hasConceptScore W2968407633C197934379 @default.
• W2968407633 hasConceptScore W2968407633C2776664568 @default.
• W2968407633 hasConceptScore W2968407633C2777180221 @default.
• W2968407633 hasConceptScore W2968407633C2778715236 @default.

• next